

XX Myeloprotection useful for treating patients undergoing e.g.
 XX chemotherapy or radiation therapy comprises administering an effective
 XX amount of a myeloid progenitor inhibitory factor-2 N terminal deletion
 XX mutant polypeptide -
 XX (150, 500); Page 194; 258pp; English.
 XX The present invention describes a myeloprotection method (M1) comprising
 XX administering an effective amount of a myeloid progenitor inhibitory
 XX factor-2 (MPF-2) N-terminal deletion mutant polypeptide (1) to an
 XX individual undergoing therapy. Also described are: (1) modulated
 XX leukaemopoietic stem cells comprising: (a) contacting the cells with a
 XX peptide as in (M1); and (b) ex vivo expansion of haematopoietic stem
 XX cells comprising contacting bone marrow with a peptide as in (M1);
 XX (2) inhibiting proliferation of leukaemia cells or mobilising stem
 XX cells, comprising administering a peptide as in (M1) to an individual;
 XX and (3) protecting HSP- α C cells comprising contacting the cells with a
 XX peptide as in (M1). (1) has neutrotropic and cytostatic activity. (1) is
 XX useful for modulating haematopoietic stem cells, for ex vivo expansion
 XX of haematopoietic stem cells, for inhibiting proliferation of leukaemia
 XX cells, for protecting HSP- α C cells, for stem cell mobilisation, and for
 XX myeloprotection in an individual undergoing chemotherapy or radiation
 XX therapy. Human chemokine-beta-6 (CK-beta-6) agonist and antagonist
 XX proteins and encoding DNA sequences, and a procedure for producing such
 XX proteins by recombinant techniques are also described in the present
 XX invention. The ck-beta-6 antagonists can be used in the treatment of
 XX rheumatoid arthritis, lung inflammation, allergy, asthma, infectious
 XX diseases and to prevent inflammation and atherosclerosis. AA021521 to
 XX AA025540 and AA067918 to AA090006 are sequences used in the
 XX exemplification of the present invention.
 XX Sequence 45 AA:

Query Match Identity Score 241; Db 22; Length 45;
 Best Local Similarity 100.0%; Pos. 31; Pos. 241; 240-255;
 Matches 45; Conserved 0; Mismatches 0; Indels 0; Gaps 0;

27 1 TSSNMEFWKKEPRRWVYVETFEEDKACVETFEEDKACVET
 10 1 TSSNMEFWKKEPRRWVYVETFEEDKACVETFEEDKACVET

RESULT 4
 AA097961
 H AA097961 standard; Protein; 46 AA.
 AA097961

10 AA097961 (first entry)

XX Human chemokine-beta-6 related protein SEQ ID NO:14.
 XX Human chemokine-beta-6; CK-beta-6; MPF-2; mutant; allergy; asthma;
 XX myeloid progenitor inhibitory factor-2; rheumatoid arthritis;
 XX lung inflammation; infectious disease; inflammation; atherosclerosis;
 XX chemotherapy; radiation therapy; neutrotropic cytostatic; leukaemia;
 XX haematopoietic stem cell; proliferation inhibition; myeloprotection;
 XX stem cell mobilisation.

XX 1679; 240pp.

XX W 200100828-A1.

XX 10 MAY 2001.

XX 25 MAY 2000; 2000W0-0529651.

XX 25 MAY 1999; 9405-0161400.

XX (HUMAN) HUMAN GEN ME 501 1N0.

XX GZDOLZOWSKI KJ, SULEJDA TW, KRZAKI BL.

DB 2001004794-01.
 XX Myeloprotection useful for treating patients undergoing e.g.
 XX chemotherapy or radiation therapy comprises administering an effective
 XX amount of a myeloid progenitor inhibitory factor-2 N terminal deletion
 XX mutant polypeptide -
 XX (150, 500); Page 194; 258pp; English.
 XX The present invention describes a myeloprotection method (M1) comprising
 XX administering an effective amount of a myeloid progenitor inhibitory
 XX factor-2 (MPF-2) N-terminal deletion mutant polypeptide (1) to an
 XX individual undergoing therapy. Also described are: (1) modulated
 XX leukaemopoietic stem cells comprising: (a) contacting the cells with a
 XX peptide as in (M1); and (b) ex vivo expansion of haematopoietic stem
 XX cells comprising contacting bone marrow with a peptide as in (M1);
 XX (2) inhibiting proliferation of leukaemia cells or mobilising stem
 XX cells, comprising administering a peptide as in (M1) to an individual;
 XX and (3) protecting HSP- α C cells comprising contacting the cells with a
 XX peptide as in (M1). (1) has neutrotropic and cytostatic activity. (1) is
 XX useful for modulating haematopoietic stem cells, for ex vivo expansion
 XX of haematopoietic stem cells, for inhibiting proliferation of leukaemia
 XX cells, for protecting HSP- α C cells, for stem cell mobilisation, and for
 XX myeloprotection in an individual undergoing chemotherapy or radiation
 XX therapy. Human chemokine-beta-6 (CK-beta-6) agonist and antagonist
 XX proteins and encoding DNA sequences, and a procedure for producing such
 XX proteins by recombinant techniques are also described in the present
 XX invention. The ck-beta-6 antagonists can be used in the treatment of
 XX rheumatoid arthritis, lung inflammation, allergy, asthma, infectious
 XX diseases and to prevent inflammation and atherosclerosis. AA021521 to
 XX AA025540 and AA067918 to AA090006 are sequences used in the
 XX exemplification of the present invention.
 XX Sequence 45 AA:

Query Match Identity Score 241; Db 22; Length 45;
 Best Local Similarity 100.0%; Pos. 31; Pos. 241; 240-255;
 Matches 45; Conserved 0; Mismatches 0; Indels 0; Gaps 0;

27 1 TSSNMEFWKKEPRRWVYVETFEEDKACVETFEEDKACVET
 10 1 TSSNMEFWKKEPRRWVYVETFEEDKACVETFEEDKACVET

RESULT 4
 AA097961
 H AA097961 standard; Protein; 46 AA.
 AA097961

10 AA097961 (first entry)

XX Human chemokine-beta-6 related protein SEQ ID NO:14.
 XX Human chemokine-beta-6; CK-beta-6; MPF-2; mutant; allergy; asthma;
 XX myeloid progenitor inhibitory factor-2; rheumatoid arthritis;
 XX lung inflammation; infectious disease; inflammation; atherosclerosis;
 XX chemotherapy; radiation therapy; neutrotropic cytostatic; leukaemia;
 XX haematopoietic stem cell; proliferation inhibition; myeloprotection;
 XX stem cell mobilisation.

XX 1679; 240pp.

XX W 200100828-A1.

XX 10 MAY 2001.

XX 25 MAY 2000; 2000W0-0529651.

XX 25 MAY 1999; 9405-0161400.

XX (HUMAN) HUMAN GEN ME 501 1N0.

XX Homo sapiens.
 XX W20100829-A1.
 XX W20010829-A1.
 XX 03 MAY 2001.
 XX 25 OCT 2000; 2000W0-0S29551.
 XX 25 OCT 1999; 990S-0161400.
 XX (HUMAN) HUMAN GENOME SCI INC.
 XX Human Genome Project.
 XX W20100829-A1.
 XX W20100829-A1.
 XX Myeloprotection useful for treating patients undergoing cell.
 XX chemotherapeutic radiation therapy comprises administering an effective
 XX amount of a myeloid progenitor inhibitory factor-2 N-terminal deletion
 XX mutant polypeptide.
 XX Disclosures, Page 216; 248pp; English.
 XX The present invention describes a myeloprotection method (M1) comprising
 XX administering an effective amount of a myeloid progenitor inhibitory
 XX factor-2 (M1P-2) N-terminal deletion mutant polypeptide (1) to an
 XX individual undergoing therapy. Also described are: (1) modulating
 XX haematopoietic stem cells comprising: (a) contacting the cells with a
 XX peptide as in (M1); and (b) ex vivo expansion of haematopoietic stem
 XX cells comprising contacting bone marrow with a peptide as in (M1);
 XX (c) inhibiting proliferation of leukaemia cells or mobilising stem
 XX cells, comprising administering a peptide as in (M1) to an individual;
 XX and (d) protecting BPP-CFC cells comprising contacting the cells with a
 XX peptide as in (M1). (1) has neutrophilic and cytostatic activity. (1) is
 XX useful for modulating haematopoietic stem cells for ex vivo expansion
 XX of haematopoietic stem cells, for inhibiting proliferation of leukaemia
 XX cells, for protecting BPP-CFC cells, for stem cell mobilisation, and for
 XX myeloprotection in an individual undergoing chemotherapy or radiation
 XX therapy. Human chemokine-beta-6 (CK-beta-6) antagonist and antagonist
 XX proteins and encoding RNA sequences, and a procedure for producing such
 XX proteins by recombinant techniques are also described in the present
 XX invention. The CK-beta-6 antagonists can be used in the treatment of
 XX rheumatoid arthritis, lung inflammation, allergy, asthma, infectious
 XX diseases and to prevent inflammation and atherosclerosis. AAB21521 to
 XX AAB21540 and AAB21513 to AAB21536 are sequences used in the
 XX exemplification of the present invention.
 XX Sequence: 49 AA:
 XX
 XX Query: Batch: 100.00; Score: 241; DB: 22; Length: 49;
 XX Best Local Similarity: 100.00; Pred. No.: 2; E: 2e-25;
 XX Matches: 49; Mismatch: 0; Mismatch: 0; Mismatch: 0;
 XX
 XX 25 1 ESPSVMEFVSERFENRVSYSLSSESTTKAWEIETKKEWQWV 45
 XX 26 1 ESPSVMEFVSERFENRVSYSLSSESTTKAWEIETKKEWQWV 45
 XX
 XX FESELI 10
 XX AAB21520 standard; Protein: 50 AA.
 XX
 XX AAB21520
 XX 1 AAB21520 (1st contig)
 XX
 XX Human chemokine-beta-6 related protein SEQ ID NO:23.
 XX Human chemokine-beta-6, CK-beta-6, MIP-2, myeloid progenitor
 XX myeloid progenitor inhibitory factor-2, tumour necrosis factor-2,
 XX lung inflammation; infectious disease; inflammation; atherosclerosis;
 XX chemotherapeutic radiation therapy; neutrophilic cytostatic; leukaemia;
 XX haematopoietic stem cell; proliferation inhibition; myeloprotection;

XX stem cell mobilisation.
 XX Homo sapiens.
 XX W20010829-A1.
 XX 03 MAY 2001.
 XX 25 OCT 2000; 2000W0-0S29551.
 XX 25 OCT 1999; 990S-0161400.
 XX (HUMAN) HUMAN GENOME SCI INC.
 XX Human Genome Project.
 XX W20100829-A1.
 XX W20100829-A1.
 XX Myeloprotection useful for treating patients undergoing cell.
 XX chemotherapeutic radiation therapy comprises administering an effective
 XX amount of a myeloid progenitor inhibitory factor-2 N-terminal deletion
 XX mutant polypeptide.
 XX Disclosures, Page 19; 248pp; English.
 XX The present invention describes a myeloprotection method (M1) comprising
 XX administering an effective amount of a myeloid progenitor inhibitory
 XX factor-2 (M1P-2) N-terminal deletion mutant polypeptide (1) to an
 XX individual undergoing therapy. Also described are: (1) modulating
 XX haematopoietic stem cells comprising: (a) contacting the cells with a
 XX peptide as in (M1); and (b) ex vivo expansion of haematopoietic stem
 XX cells comprising contacting bone marrow with a peptide as in (M1);
 XX (c) inhibiting proliferation of leukaemia cells or mobilising stem
 XX cells, comprising administering a peptide as in (M1) to an individual;
 XX and (d) protecting BPP-CFC cells comprising contacting the cells with a
 XX peptide as in (M1). (1) has neutrophilic and cytostatic activity. (1) is
 XX useful for modulating haematopoietic stem cells for ex vivo expansion
 XX of haematopoietic stem cells, for inhibiting proliferation of leukaemia
 XX cells, for protecting BPP-CFC cells, for stem cell mobilisation, and for
 XX myeloprotection in an individual undergoing chemotherapy or radiation
 XX therapy. Human chemokine-beta-6 (CK-beta-6) antagonist and antagonist
 XX proteins and encoding RNA sequences, and a procedure for producing such
 XX proteins by recombinant techniques are also described in the present
 XX invention. The CK-beta-6 antagonists can be used in the treatment of
 XX rheumatoid arthritis, lung inflammation, allergy, asthma, infectious
 XX diseases and to prevent inflammation and atherosclerosis. AAB21521 to
 XX AAB21540 and AAB21513 to AAB21536 are sequences used in the
 XX exemplification of the present invention.
 XX Sequence: 50 AA:
 XX
 XX Query: Batch: 100.00; Score: 271; DB: 22; Length: 50;
 XX Best Local Similarity: 100.00; Pred. No.: 2; E: 2e-26;
 XX Matches: 49; Mismatch: 1; Mismatch: 0; Mismatch: 0;
 XX
 XX 27 1 ESPSVMEFVSERFENRVSYSLSSESTTKAWEIETKKEWQWV 45
 XX 28 1 ESPSVMEFVSERFENRVSYSLSSESTTKAWEIETKKEWQWV 45
 XX 29 1 ESPSVMEFVSERFENRVSYSLSSESTTKAWEIETKKEWQWV 45
 XX 30 1 ESPSVMEFVSERFENRVSYSLSSESTTKAWEIETKKEWQWV 45
 XX
 XX FESELI 11
 XX AAB21520 standard; Protein: 50 AA.
 XX
 XX AAB21520
 XX 1 AAB21520 (1st contig)
 XX
 XX Human chemokine-beta-6 related protein SEQ ID NO:24.
 XX Human chemokine-beta-6, CK-beta-6, MIP-2, myeloid progenitor
 XX myeloid progenitor inhibitory factor-2, tumour necrosis factor-2,
 XX lung inflammation; infectious disease; inflammation; atherosclerosis;
 XX chemotherapeutic radiation therapy; neutrophilic cytostatic; leukaemia;
 XX haematopoietic stem cell; proliferation inhibition; myeloprotection;



Wed May 14 13:30:35 2003

us 09 419 281-23.rai

page 7




```

10 00000000 PRELIMINARY: PRE: 91 AA.
11 00000000
12 00000000 (TREMbled, 21, treated)
13 00000000 (TREMbled, 21, last sequence update)
14 00000000 (TREMbled, 21, last annotation update)
15 00000000
16 00000000
17 00000000 (Chickoo)
18 00000000 Chordata: Craniata: Vertebrata: Osteichthyes:
19 00000000 Aves: Neornithes: Galliformes: Phasianidae: Phasianinae:
20 00000000
21 00000000
22 00000000
23 00000000
24 00000000
25 00000000
26 00000000
27 00000000
28 00000000
29 00000000
30 00000000
31 00000000
32 00000000
33 00000000
34 00000000
35 00000000
36 00000000
37 00000000
38 00000000
39 00000000
40 00000000
41 00000000
42 00000000
43 00000000
44 00000000
45 00000000
46 00000000
47 00000000
48 00000000
49 00000000
50 00000000
51 00000000
52 00000000
53 00000000
54 00000000
55 00000000
56 00000000
57 00000000
58 00000000
59 00000000
60 00000000
61 00000000
62 00000000
63 00000000
64 00000000
65 00000000
66 00000000
67 00000000
68 00000000
69 00000000
70 00000000
71 00000000
72 00000000
73 00000000
74 00000000
75 00000000
76 00000000
77 00000000
78 00000000
79 00000000
80 00000000
81 00000000
82 00000000
83 00000000
84 00000000
85 00000000
86 00000000
87 00000000
88 00000000
89 00000000
90 00000000
91 00000000
92 00000000
93 00000000
94 00000000
95 00000000
96 00000000
97 00000000
98 00000000
99 00000000
100 00000000

```

```

10 00000000 PRELIMINARY: PRE: 91 AA.
11 00000000
12 00000000 (TREMbled, 21, treated)
13 00000000 (TREMbled, 21, last sequence update)
14 00000000 (TREMbled, 21, last annotation update)
15 00000000
16 00000000
17 00000000 (Chickoo)
18 00000000 Chordata: Craniata: Vertebrata: Osteichthyes:
19 00000000 Aves: Neornithes: Galliformes: Phasianidae: Phasianinae:
20 00000000
21 00000000
22 00000000
23 00000000
24 00000000
25 00000000
26 00000000
27 00000000
28 00000000
29 00000000
30 00000000
31 00000000
32 00000000
33 00000000
34 00000000
35 00000000
36 00000000
37 00000000
38 00000000
39 00000000
40 00000000
41 00000000
42 00000000
43 00000000
44 00000000
45 00000000
46 00000000
47 00000000
48 00000000
49 00000000
50 00000000
51 00000000
52 00000000
53 00000000
54 00000000
55 00000000
56 00000000
57 00000000
58 00000000
59 00000000
60 00000000
61 00000000
62 00000000
63 00000000
64 00000000
65 00000000
66 00000000
67 00000000
68 00000000
69 00000000
70 00000000
71 00000000
72 00000000
73 00000000
74 00000000
75 00000000
76 00000000
77 00000000
78 00000000
79 00000000
80 00000000
81 00000000
82 00000000
83 00000000
84 00000000
85 00000000
86 00000000
87 00000000
88 00000000
89 00000000
90 00000000
91 00000000
92 00000000
93 00000000
94 00000000
95 00000000
96 00000000
97 00000000
98 00000000
99 00000000
100 00000000

```


